PHA-543,613
Identifiers | |
---|---|
| |
CAS Number | 478149-53-0 |
PubChem (CID) | 11493927 |
IUPHAR/BPS | 3998 |
ChemSpider | 8105752 |
ChEMBL | CHEMBL214268 |
ECHA InfoCard | 100.189.975 |
Chemical and physical data | |
Formula | C15H17N3O2 |
Molar mass | 271.314 |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
PHA-543,613 is a drug that acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors, with a high level of brain penetration and good oral bioavailability. It is under development as a possible treatment for cognitive deficits in schizophrenia.[1]
References
- ↑ Wishka, D.; Walker, D.; Yates, K.; Reitz, S.; Jia, S.; Myers, J.; Olson, K.; Jacobsen, E.; Wolfe, M.; Groppi, V.; Hanchar, A. J.; Thornburgh, B. A.; Cortes-Burgos, L. A.; Wong, E. H. F.; Staton, B. A.; Raub, T. J.; Higdon, N. R.; Wall, T. M.; Hurst, R. S.; Walters, R. R.; Hoffmann, W. E.; Hajos, M.; Franklin, S.; Carey, G.; Gold, L. H.; Cook, K. K.; Sands, S. B.; Zhao, S. X.; Soglia, J. R.; Kalgutkar, A. S. (2006). "Discovery of N-(3R)-1-azabicyclo2.2.2oct-3-ylfuro2,3-cpyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship". Journal of Medicinal Chemistry. 49 (14): 4425–4436. doi:10.1021/jm0602413. PMID 16821801.
AChE inhibitors | |
---|---|
Others |
This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.